Oncology

News

FDA clears subcutaneous Keytruda in a boost to MSD

MSD's Keytruda will soon be available as a subcutaneous injection, improving convenience for patients and defending it from a looming patent loss.

Oncology

Prostate Cancer Awareness blue ribbon on blue background

Current and future standard of care in prostate cancer

Despite recent advancements in the field of prostate cancer treatment, there remain distinct gaps in the current standard of care needing improvement.

News

Imfinzi becomes first NHS drug for aggressive lung cancer

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

Oncology

12 Questions with Rick Coope

Rick Coope is General Manager at Menarini Stemline UK, Ireland, and the Nordics.

Digital

AI medicines are coming: Building the foundations for discov...

News

J&J claims FDA okay for bladder cancer drug TAR-200

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.

FDA clears subcutaneous Keytruda in a boost to MSD

Current and future standard of care in prostate cancer

Imfinzi becomes first NHS drug for aggressive lung cancer

12 Questions with Rick Coope

AI medicines are coming: Building the foundations for discov...

J&J claims FDA okay for bladder cancer drug TAR-200

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Oncology

Editor's Picks